InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.105 -0.008 (-6.67%)+
Announcement
Release
1 Jul 2026 10:00AM
Price at Release
$0.113
Full Release
download
Summary
Imugene Limited reported an additional complete response in a patient from the concurrent BTKi cohort of its Phase 1b trial of azer-cel, an allogeneic CAR T cell therapy targeting CD19 to treat blood cancers. This marks significant progress, particularly for the first Mantle Cell Lymphoma patient treated in the study who had previously failed BTKi therapy. The trial, which is taking place across multiple sites in the US and Australia, focuses on patients who have relapsed on or are refractory to BTKi therapy. Azer-cel offers a promising therapeutic option in the global BTKi market, valued at approximately US$12 billion in 2025.
Key Points
  • Imugene Limited announces an additional complete response in the concurrent BTKi cohort of its azer-cel Phase 1b trial.
  • The first Mantle Cell Lymphoma patient in the study achieved a complete response after previous failure with BTKi therapy.
  • Azer-cel is an off-the-shelf, allogeneic CAR T cell therapy targeting CD19 for treating blood cancers.
  • The Phase 1b trial includes patients who have relapsed on or are refractory to BTKi therapy.
  • The global BTKi market was valued at approximately US$12 billion in 2025.
  • The study is conducted across ten US and five Australian sites, with ongoing patient enrollment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.